A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Hepatic Steatosis and Elevated Liver Stiffness

Trial Profile

A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Hepatic Steatosis and Elevated Liver Stiffness

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs GS 0976 (Primary) ; GS 9674 (Primary) ; Selonsertib (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 13 Apr 2018 Results presented in the, Gilead Sciences media release.
    • 13 Apr 2018 According to a Gilead Sciences media release, the first 12-Week data of the combination therapy was presented at the The International Liver Congress (2018).
    • 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top